drugset / Trial / NCT05430958
Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This is an open label, phase 1 clinical trial of an intra-dermal booster dose of INO-4800 alone or in combination with INO-9112 followed by electroporation (EP) among healthy adults at least 18 years of age, who previously completed their primary immunization series with mRNA vaccines against SARS-CoV-2 within 6-12 months prior to the booster dose.
Timeline
- Start
- 2022-10
- Primary completion
- 2024-03
- Completion
- 2024-03
Outcome
Outcome not reported
Stopped (Business): “Study was withdrawn due to sponsor decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INO-9112 | Unknown | 0.05 mg | Intravenous |
| Subject | INO-9112 | Unknown | 0.1 mg | Intravenous |
| Subject | INO-9112 | Unknown | 0.2 mg | Intravenous |
| Subject | INO-9112 | Unknown | 0.4 mg | Intravenous |
| Subject | RELUSCOVTOGENE RALAPLASMID | Vaccine | 0.8 mg | Intravenous |
| Subject | RELUSCOVTOGENE RALAPLASMID | Vaccine | 1.6 mg | Intravenous |